1H3.SI stock down 50.00% intraday on 23 Mar 2026: watch liquidity and forecasts

1H3.SI stock plunged -50.00% intraday to S$0.001 on 23 Mar 2026, marking it among the top losers on the Singapore Exchange (SES). The sell-off followed heavy volume of 105,100,000 shares and pushed market attention toward liquidity and valuation signals. Clearbridge Health Limited (1H3.SI) now trades well below its 50-day average and 200-day average, a red flag for short-term traders on the Catalist board. We explain what moved the price, the balance sheet signals, and where analyst models place the stock next

1H3.SI stock: Intraday price action and volume

The immediate driver was a one-day fall of -50.00%, with the price at S$0.001 and the previous close at S$0.002. Volume surged to 105,100,000 shares versus an average of 3,993,383, indicating forced liquidations or block selling. The intraday range was narrow, with day low and day high both at S$0.001, showing trades clustered at the new low. Traders should note the extreme daily drop and very thin price increments on the SES Catalist board

1H3.SI stock: Financials and valuation metrics

Clearbridge Health Limited reports revenue of S$9.93 million for 2025 and a loss of S$12.91 million, a widening versus 2024. Key valuation metrics show a price to sales ratio of 0.43 and price to book ratio of 0.95, with market cap near S$4,295,821. Cash per share is S$0.00030, book value per share S$0.00159, and net income per share -S$0.00391, underlining negative profitability. These ratios signal a small-cap healthcare group under stress despite modest revenue

1H3.SI stock: Technicals and trading signals

Technical indicators show weakness: RSI at 37.32 and CCI at -115.67, both consistent with oversold conditions. Price averages are below shorter-term levels with a 50-day average of S$0.00194 and 200-day average S$0.00248, pointing to a downtrend. On-balance volume reads 23,112,400, which confirms recent heavy selling. For active traders, a stop-loss discipline is prudent given the stock’s thin tick size and elevated intraday volatility

Meyka AI rates 1H3.SI with a score out of 100 and forecast

Meyka AI rates 1H3.SI with a score out of 100: 62 / 100 which maps to Grade B and a suggestion to HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a one-year baseline price of S$0.005 and a three-year target of S$0.012. Versus the current S$0.001, the one-year projection implies roughly +400.00% upside and the three-year projection implies roughly +1,100.00% upside. Forecasts are model-based projections and not guarantees. These grades are not guaranteed and we are not financial advisors

1H3.SI stock: Sector context and risks

Clearbridge operates in Healthcare diagnostics and clinics where peers show stronger margins and higher average PE. The sector average net margin sits near 26.52%, while Clearbridge reports negative margins. Key risks include continued losses, low cash per share, and receivables days of 113.63, which can pressure working capital. Regulatory or contract changes in Singapore and regional markets could also affect operations, raising execution risk for any turnaround plan

1H3.SI stock: Short-term outlook and trading considerations

Near term, price support is likely at S$0.001 given the year low and recent prints, while resistance sits near the 50-day average at S$0.002. For traders, liquidity risk is paramount; shares outstanding are 4,295,820,825 and average volume is low relative to today’s spike. Analysts and active investors should track company updates, the earnings announcement dated 19 Aug 2026, and any capital actions that could dilute holders. For a conservative portfolio, plan position size to limit downside exposure

Final Thoughts

Key takeaways for 1H3.SI stock: the intraday -50.00% drop to S$0.001 on 23 Mar 2026 came with outsized volume of 105,100,000 shares and highlights acute liquidity pressure on this small-cap Healthcare name listed on the SES. Valuation ratios such as P/S 0.43 and P/B 0.95 look inexpensive, but losses and weak cash per share point to operational stress. Meyka AI’s forecast model projects a one-year baseline of S$0.005 (implying about +400.00% from current price) and a three-year target of S$0.012. These model outputs assume a recovery in margins and improved working capital. For intraday and short-term traders, focus on trade size, stop-loss discipline, and any company announcements. Long-term investors must weigh the model upside against execution risk and negative earnings. For complete company filings and recent financials, see the Clearbridge Health site and the detailed market summary StockAnalysis report and Clearbridge Health corporate site. Meyka AI provides this as an AI-powered market analysis platform; forecasts are projections and not guarantees

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.